Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2017-07-31 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Number of shares and votes in NeuroVive Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces an increase in the total number of shares and votes in NeuroVive Pharmaceutical AB due to a directed rights issue and a subscription options program. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not an earnings release, an annual report, or a management change announcement. Given the specific nature of the announcement regarding the total share count following a capital event, SHA is the most appropriate classification.
2017-07-31 English
Antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement from NeuroVive Pharmaceutical AB dated July 31, 2017. The core content explicitly states that the total number of shares and votes has increased due to a directed share issue and a warrant program completed in July. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). The mention of the EU Market Abuse Regulation suggests it is a mandatory regulatory disclosure, but SHA is the most specific category.
2017-07-31 Swedish
NeuroVive tecknar private placement-avtal med Esousa Holdings LLC och genomför den första emissionen av Units
Share Issue/Capital Change Classification · 1% confidence The document announces that NeuroVive has signed an agreement for a private placement (a form of fundraising/financing) with Esousa Holdings LLC and details the first issuance of Units (shares and warrants) as part of this transaction. Key phrases include 'private placement-avtal' (private placement agreement), 'tillföra bolaget totalt 9 miljoner svenska kronor' (bring the company a total of 9 million SEK), 'emission av Units' (issuance of Units), and 'kapitalanskaffning' (capital raising). This directly corresponds to the definition of Capital/Financing Update (CAP). The document is a formal announcement detailing the terms of the capital raise, not a general regulatory filing (RNS) or a report itself.
2017-07-18 Swedish
NeuroVive signs private placement agreement with Esousa Holdings LLC and issues units
Share Issue/Capital Change Classification · 1% confidence The document announces that NeuroVive has signed a non-brokered private placement agreement to raise 9 million SEK through the issue of Units (shares and warrants) to Esousa Holdings LLC. This involves the issuance of new shares and warrants, resulting in an increase in share capital and outstanding shares. This activity directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an earnings release, annual report, or a general regulatory filing, but a specific announcement about capital procurement.
2017-07-18 English
EQS-News: Edison Investment Research Limited: Edison issues initiation on NeuroVive Pharmaceutical (NVP)
Regulatory Filings Classification · 1% confidence The document is an announcement from Edison Investment Research regarding the initiation of research on NeuroVive Pharmaceutical. It provides a summary of the research findings and includes a link to view the full report. Since it is an announcement of a report rather than the report itself, and it does not fit into the specific categories of financial filings (like 10-K or IR), it is classified as a Regulatory Filing (RNS) which serves as the fallback for miscellaneous announcements. Q1 2017
2017-06-29 English
NeuroVive and Yungjin Pharm start clinical development in genetic mitochondrial disease
Regulatory Filings Classification · 1% confidence The document announces the start of a clinical phase I study for a drug (KL1333) and details the collaboration between NeuroVive and Yungjin Pharm. It includes specific dates (June 27, 2017), mentions clinical trial registration numbers, and discusses drug development progress. This type of announcement, focusing on operational milestones, partnerships, and clinical progress, is typically classified as a general regulatory announcement or news release that doesn't fit the specific financial report categories (like 10-K, ER, or IR). Since it is a specific operational update that is not a formal financial report, a management discussion, or a director dealing report, the most appropriate general category is Regulatory Filings (RNS), which serves as a catch-all for significant, non-standard regulatory disclosures.
2017-06-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.